These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 12804052)

  • 41. Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen.
    Theuer CP; Leigh BR; Multani PS; Allen RS; Liang BC
    Biotechnol Annu Rev; 2004; 10():265-95. PubMed ID: 15504711
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status].
    Emmanouilides C
    Rev Esp Med Nucl; 2006; 25(1):42-54. PubMed ID: 16540013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).
    Chiesa C; Botta F; Coliva A; Maccauro M; Devizzi L; Guidetti A; Carlo-Stella C; Seregni E; Gianni MA; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1745-57. PubMed ID: 19455328
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Witzig TE
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):74-8. PubMed ID: 11226003
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital.
    Turner JH; Martindale AA; Boucek J; Claringbold PG; Leahy MF
    Cancer Biother Radiopharm; 2003 Aug; 18(4):513-24. PubMed ID: 14503945
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry.
    Conti PS; White C; Pieslor P; Molina A; Aussie J; Foster P
    J Nucl Med; 2005 Nov; 46(11):1812-8. PubMed ID: 16269594
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
    DeNardo GL; DeNardo SJ; O'Donnell RT; Kroger LA; Kukis DL; Meares CF; Goldstein DS; Shen S
    Clin Lymphoma; 2000 Sep; 1(2):118-26. PubMed ID: 11707820
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues.
    Silverman DH; Delpassand ES; Torabi F; Goy A; McLaughlin P; Murray JL
    Cancer Treat Rev; 2004 Apr; 30(2):165-72. PubMed ID: 15023434
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy.
    Jacobs SA; Vidnovic N; Joyce J; McCook B; Torok F; Avril N
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7146s-7150s. PubMed ID: 16203814
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Winter JN; Inwards DJ; Spies S; Wiseman G; Patton D; Erwin W; Rademaker AW; Weitner BB; Williams SF; Tallman MS; Micallef I; Mehta J; Singhal S; Evens AM; Zimmer M; Molina A; White CA; Gordon LI
    J Clin Oncol; 2009 Apr; 27(10):1653-9. PubMed ID: 19255322
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Borghaei H; Schilder RJ
    Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):4-9. PubMed ID: 14762738
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin).
    Hernandez MC; Knox SJ
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):6-10. PubMed ID: 14710397
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma.
    Hagenbeek A; Lewington V
    Ann Oncol; 2005 May; 16(5):786-92. PubMed ID: 15802280
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma.
    Borghaei H; Wallace SG; Schilder RJ
    Clin Lymphoma; 2004 Oct; 5 Suppl 1():S16-21. PubMed ID: 15498145
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Contribution of radioimmunotherapy to the treatment of lymphoma].
    Rizzo-Padoin N
    Ann Pharm Fr; 2008; 66(5-6):300-8. PubMed ID: 19061730
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
    Wiseman GA; Witzig TE
    Cancer Biother Radiopharm; 2005 Apr; 20(2):185-8. PubMed ID: 15869453
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial.
    Evens AM; Spies WG; Helenowski IB; Patton D; Spies S; Jovanovic BD; Miyata S; Hamilton E; Variakojis D; Chen J; Naumovski L; Rosen ST; Winter JN; Miller RA; Gordon LI
    Clin Cancer Res; 2009 Oct; 15(20):6462-71. PubMed ID: 19825958
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma.
    Scheidhauer K; Wolf I; Baumgartl HJ; Von Schilling C; Schmidt B; Reidel G; Peschel C; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1276-82. PubMed ID: 12271407
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Estimation of yttrium-90 Zevalin tumor-absorbed dose in ocular adnexal lymphoma using quantitative indium-111 Zevalin radionuclide imaging.
    Erwin WD; Esmaeli B
    Nucl Med Commun; 2009 Sep; 30(9):681-6. PubMed ID: 19528874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.